Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "Wockhardt"

48 News Found

Vakrangee to distribute Corival products
Supply Chain | November 15, 2021

Vakrangee to distribute Corival products

Vakrangee’s distribution network across rural India will help penetrate underserved markets


Alarming rise in diabetes amongst children and adolescents in India
News | November 14, 2021

Alarming rise in diabetes amongst children and adolescents in India

The rise in cases amongst the young is a cause for concern. A few specialists gave us a perspective on the issue


Domestic growth to the fore as US weakness persists: ICICI Direct
News | October 19, 2021

Domestic growth to the fore as US weakness persists: ICICI Direct

ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report


Semglee approval to provide huge opportunities in the US insulin biosimilar market
Biotech | August 19, 2021

Semglee approval to provide huge opportunities in the US insulin biosimilar market

FDA approval of the first interchangeable biosimilar insulin will drive the US Insulin biosimilar market, says Kuick Research.


Meddo acquires Doxper in a cash and stock deal
Healthcare | August 03, 2021

Meddo acquires Doxper in a cash and stock deal

This deal makes Meddo, one of the largest health-tech players in India


Hugely successful vaccination roll out made possible by India-UK partnership
Policy | July 28, 2021

Hugely successful vaccination roll out made possible by India-UK partnership

The contribution of Wockhardt at Wrexham is one of the best examples of the success and significant potential of India-UK partnerships in the healthcare sector


Outlook intact for Dr. Reddy's Laboratories : ICICI Securities
News | May 18, 2021

Outlook intact for Dr. Reddy's Laboratories : ICICI Securities

India sales grew 23.5% YoY with consolidation of Wockhardt products


NPPA brings 80 plus medicines under price regulation
News | March 22, 2021

NPPA brings 80 plus medicines under price regulation

NPPA also fixed retail price of 76 new drugs in the meeting dated 10th March 2021 to be launched by existing manufacturers including off-patent Anti-diabetic drugs allowing due benefit of patent expiry to the patients.